VanEck Pharmaceutical ETF (PPH)

NasdaqGM: PPH · Real-Time Price · USD

113.62

-0.44 (-0.39%)

At close: Aug 28, 2026, 3:59 PM

113.62

+0.00%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

-0.39% (1D)

Bid	109.61
Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	n/a
	n/a
	n/a
	25.16
	n/a
P/B (ttm)	n/a
P/S (ttm)	n/a
Earnings Date	n/a

Ask	110.12
Volume	272,067
Avg. Volume (20D)	278,058
Open	113.59
Previous Close	114.06
Day's Range	113.15 - 113.87
52-Week Range	85.91 - 118.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About PPH

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified....

[Read more]

Industry n/a

Sector n/a

IPO Date Feb 1, 2000

Employees n/a

Stock Exchange NasdaqGM

Ticker Symbol PPH

Full Company Profile

Financial Performance

In undefined, VanEck Pharmaceutical ETF's revenue was n/a, an increase of undefined% compared to the previous year's n/a. Earnings were n/a, an increase of undefined%.

Financial Statements

News

3 days ago · Zacks

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

1 week ago · 24/7 Wall St.

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last...